Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patient’s own cells.
For the first time, NYSCF scientists generated induced pluripotent stem (iPS) cells lines from skin samples of patients with primary progressive multiple sclerosis and further, they developed an accelerated protocol to induce these stem cells into becoming oligodendrocytes, the myelin-forming cells of the central nervous system implicated in multiple sclerosis and many other diseases.
Existing protocols for producing oligodendrocytes had taken almost half a year to produce, limiting the ability of researchers to conduct their research. This study has cut that time approximately in half, making the ability to utilize these cells in research much more feasible.
Stem cell lines and oligodendrocytes allow researchers to “turn back the clock” and observe how multiple sclerosis develops and progresses, potentially revealing the onset of the disease at a cellular level long before any symptoms are displayed. The improved protocol for deriving oligodendrocyte cells will also provide a platform for disease modeling, drug screening, and for replacing the damaged cells in the brain with healthy cells generated using this method.
“We are so close to finding new treatments and even cures for MS. The enhanced ability to derive the cells implicated in the disease will undoubtedly accelerate research for MS and many other diseases,” said Susan L. Solomon, NYSCF Chief Executive Officer.
The Latest on: Cell replacement therapy
via Google News
The Latest on: Cell replacement therapy
- MeiraGTx: An Exciting Gene Therapy Pick In March 2020on March 24, 2020 at 10:34 am
GAD is one of the most promising gene therapy candidates targeting Parkinson's disease. MeiraGTx has demonstrated proof-of-concept for AAV-RPE65 in inherite ...
- COVID-19: Abnormal Clotting Common in More Severe Diseaseon March 24, 2020 at 7:33 am
"The virus can bind to the endothelial cells and may cause damage to the blood vessel especially the microcirculation ... paying attention to fluid balance Continuous renal replacement therapy to ...
- Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidateson March 22, 2020 at 11:00 pm
Regulated information Regulatory authorities approve JTA Phase III study in osteoarthritic knee pain and ALLOB Phase IIb study in difficult fractures ...
- Cancer labs reach beyond exhausted T cellson March 18, 2020 at 6:06 am
T cells race to the scene in cancer and infection. To tease out what is special in cancer, scientists widen their scope and tool sets. “I’m a basic scientist. I did not get into these studies to try ...
- Cancer Gene Therapy Market Comprehensive Analysis, Growth Forecast from 2019 to 2025on March 17, 2020 at 5:42 am
Market Study Report LLC has added a new report on Cancer Gene Therapy market that provides a comprehensive review of this industry with respect to the driving forces influencing the market size.
- US Nuclear and Grapheton Provide Significant Advances for Parkinson’s Disease Therapyon March 17, 2020 at 5:32 am
via NEWMEDIAWIRE -- The next chapter in US Nuclear’s (OTC: UCLE) brain-machine interface revolution is treating Parkinson’s Disease. Over 10 million people live with Parkinson’s Disease worldwide.
- Stem cells to help the hearton March 12, 2020 at 12:23 pm
Cardiomyocytes derived from hiPSCs (hiPSC-CMs) may represent a potential replacement option for dead cells in such a scenario. However, certain issues remain to be addressed, such as whether hiPSC-CMs ...
- Treating sickle cell anemiaon March 12, 2020 at 11:46 am
The mutation results in the replacement of negatively charged glutamate by a neutral ... Research on sickle cell anemia has again taken center stage because of new drug therapies, cures through stem ...
- Induced Pluripotent Stem Cells Show Success in Treating Hemophilia A in Miceon March 12, 2020 at 8:27 am
DURHAM, N.C., March 12, 2020 /PRNewswire-PRWeb/ -- In a new study released today in STEM CELLS Translational Medicine (SCTM), researchers at the ...
- SSM Health Medical Minute – New therapy for blood cancer patients providing ‘landscape changing’ resultson March 11, 2020 at 5:46 pm
ST. LOUIS – Specialists at SSM Health Saint Louis University Hospital and SSM Health Cardinal Glennon Children’s Hospital have new hope for some cancer patients, through a therapy using the ...
via Bing News